| Code | CSB-RA021334MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to BI-765063, targeting signal regulatory protein alpha (SIRPα), a critical immune checkpoint receptor expressed on myeloid cells including macrophages and dendritic cells. SIRPα interacts with CD47, a "don't eat me" signal widely expressed on normal cells and frequently overexpressed on cancer cells, inhibiting phagocytosis when this interaction occurs. By blocking the SIRPα-CD47 axis, this antibody enables macrophage-mediated phagocytosis of tumor cells, representing a promising mechanism for cancer immunotherapy. Dysregulation of this pathway has been implicated in various malignancies, including acute myeloid leukemia, non-Hodgkin lymphoma, and solid tumors, where CD47 overexpression allows cancer cells to evade immune surveillance.
BI-765063 is a clinical-stage therapeutic antibody designed to selectively block SIRPα without binding to red blood cells, potentially reducing hematologic toxicity associated with CD47-targeting approaches. This biosimilar provides researchers with a valuable tool for investigating innate immune checkpoint mechanisms, studying macrophage biology, and exploring combination immunotherapy strategies in preclinical cancer models.
There are currently no reviews for this product.